Skip to main content
OpenTrials
Completed

NCT Number: NCT01612871

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

This is a biomedical and prospective study of interventional type. The trial will include 29 patients over a period of 15 months + 24 months of follow up maximum.

The study will be conduct in womens with metastatic invasive breast cancer or locally advanced breast cancer and for which treatment with tamoxifen or anti aromatase (first line hormone therapy for metastatic breast cancer) is indicated.

The main objective of this pilot study is to evaluate the feasibility to detect in the circulating blood of patients, before treatment (T0), the presence of the fifteen tissular microRNAs described in preclinical studies as possibly involved in hormone resistance/sensitivity.

In parallel of the detection of these specific miRNAs, we will conduct a larger scale analysis of circulating miRNAs in these patients before (T = 0) and after one month of treatment (T28).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Centre Val d'Aurelle - Paul Lamarque, Montpellier, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women of more than 18 years old (menopausal or not)
  • Women with metastatic invasive breast cancer or locally advanced (without surgical project), for which treatment with tamoxifen or anti aromatase

+/- LH-RH agonist, is indicated (anti-aromatase prescribed for menopausal womens; tamoxifen prescribed for both menopausal, pre menopausal or not menopausal womens).

  • Cancer hormone-expressing estrogen receptor (ER) and / or progesterone receptor (PR) (>= 10% of tumor cells by IHC technique).

Cancer HER2 negative.

  • Evaluable disease (measurable according RECIST criteria or not)
  • Any previous adjuvant hormone therapy should be discontinued for at least 21 days.
  • One or two prior metastatic lines of chemotherapy are allowed
  • General status WHO 0-2
  • The women of childbearing age must use an effective contraception for the duration of the study
  • Informed consent obtained and signed before any specific study procedure
  • Patient member in a national insurance scheme

Exclusion criteria

  • Patient already treated with hormone therapy or not having stopped the previous adjuvant hormone therapy for at least 21 days.
  • Prescription of chemotherapy and / or other targeted therapy (other than hormone therapy) for the treatment of the breast cancer
  • Any previous hormone therapy for metastatic or locally advanced (without surgical project) breast cancer
  • Known hypercalcaemia before miRNA dosage at T=0 requiring immediate biphosphonate therapy
  • Any other medical or psychiatric condition or severe or chronic laboratory abnormality making the the inclusion of the patient in the study inappropriate in the opinion of the investigator.
  • Patient unable to follow procedures, visits, examinations described in the study.
  • Pregnant women or nursing mothers will not participate in the study.
  • Patients under legal guardianship

Treatment and study plan

Tamoxifen, Letrozole , Anastrozole, Exemestane

Drug

Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :

Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day

Primary outcomes

  1. Rates of patients for which specific tissular miRNAs are detected in blood before treatment (D0)

    Time frame: 1 time point (D0) over a period of 39 months

    MiRNAs will be quantified in plasma using qPCR (quantitative Polymerase Chain Reaction) with the kit "miScriptSYBR Green PCR" (Qiagen)

Secondary outcomes

  1. Analysis of the larger-scale circulating miRNAs in plasma of these patients before (D0) and after one month (D28) of treatment with tamoxifen or anti aromatase

    Time frame: 2 time points (D0 and D28) over a period of 39 months (3 years and 3 months)

  2. Correlation between the specific miRNAs initial expression and the appearance of an objective response or clinical benefit of hormone therapy and the time to progression

    Time frame: 39 months (3 years and 3 months)

  3. Rate of objective responses, defined as the number of patients with a complete or partial response.

    Time frame: 39 months (3 years and 3 months)

  4. The time to progression, defined as the time from patient inclusion to the date of the first documented tumor progression

    Time frame: 39 months (3 years and 3 months)

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Registry information

Official study title

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer? Pilot Study.

Acronym: MIRHO

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Jun 6, 2012
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.